 Business Wire India Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences best-in-class 3T-TRACE T-Cell Receptor Antigen and Cross-Reactivity Engine discovery platform with Boehringer Ingelheims two-pronged research ... The post Boehringer Ingelheim and 3T Biosciences Join F... 